Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Abvc Biopharma Inc (ABVC)

Abvc Biopharma Inc (ABVC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,121
  • Shares Outstanding, K 12,975
  • Annual Sales, $ 150 K
  • Annual Income, $ -10,520 K
  • EBIT $ -6 M
  • EBITDA $ -6 M
  • 60-Month Beta 0.82
  • Price/Sales 46.94
  • Price/Cash Flow N/A
  • Price/Book 0.86
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.86
  • Most Recent Earnings $-0.02 on 11/14/24
  • Next Earnings Date 11/20/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.4951 +10.85%
on 11/11/24
0.7700 -28.73%
on 10/30/24
-0.0112 (-2.00%)
since 10/22/24
3-Month
0.4053 +35.41%
on 10/10/24
0.7700 -28.73%
on 10/30/24
-0.1612 (-22.70%)
since 08/22/24
52-Week
0.4053 +35.41%
on 10/10/24
2.4500 -77.60%
on 01/03/24
-1.3212 (-70.65%)
since 11/22/23

Most Recent Stories

More News
Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection

/CNW/ -- USA News Group – Hope is rising in the fight against one of the deadliest cancers in the world, as a new study recently claimed that a blood test can...

ONCY : 0.9541 (-2.64%)
CADL : 5.04 (+21.89%)
ABVC : 0.5488 (-0.20%)
CTMX : 0.8900 (+2.71%)
AMGN : 294.53 (+1.60%)
ONC.TO : 1.33 (-2.92%)
Biotech Innovations Drive Hope in Global Fight Against Pancreatic Cancer

USA News Group – Hope is rising in the fight against one of the deadliest cancers in the world, as a new study recently claimed that a blood test can accurately detect early-stage pancreatic cancer with...

ONCY : 0.9541 (-2.64%)
ONC.TO : 1.33 (-2.92%)
CADL : 5.04 (+21.89%)
ABVC : 0.5488 (-0.20%)
CTMX : 0.8900 (+2.71%)
AMGN : 294.53 (+1.60%)
ABVC Biopharma (NASDAQ: ABVC) Inks Major Licensing Agreement with Xinnovation Therapeutics for ABV-1504 and ABV-1505

Landmark Licensing Deal for ABVC in China's Growing Healthcare Market ABVC Biopharma, Inc. (NASDAQ: ABVC), a pioneer in the development

ABVC : 0.5488 (-0.20%)
ABVC BioPharma Provides Vitargus® Update on Phase II Site Initiation Visit Conducted at Srinagarind Hospital in Thailand

/PRNewswire/ -- ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS,...

ABVC : 0.5488 (-0.20%)
ABVC BioPharma Receives Registration Approval for Maitake Mushroom Dietary Supplement by the Taiwan Ministry of Health and Welfare

/PRNewswire/ -- ABVC Biopharma, Inc. ("ABVC" or the "Company") (NASDAQ: ABVC), a clinical stage biopharmaceutical company developing therapeutic solutions in...

ABVC : 0.5488 (-0.20%)
ABVC BioPharma Provides Vitargus® Update

Phase II Vitargus® Clinical Study Protocol Receives Local Ethics Committee Approval FREMONT, CA, Aug. 02, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire...

ABVC : 0.5488 (-0.20%)
ABVC Notes New Report That Estimates Global Retinal Surgical Instruments Market to Grow to $2.46 Billion by 2028

-- Growth to benefit ABVC’s Vitargus medical device product -- FREMONT, CA, July 18, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc....

ABVC : 0.5488 (-0.20%)
ABVC BioPharma Provides ADHD Phase II Part 2 Clinical Update

FREMONT, CA, July 13, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company...

ABVC : 0.5488 (-0.20%)
Zacks Places Share Value of ABVC BioPharma at $9.50

FREMONT, CA, July 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC Biopharma, Inc. (NASDAQ: ABVC), a clinical stage biopharmaceutical company...

ABVC : 0.5488 (-0.20%)
ABVC BioPharma Provides Vitargus® Update

Vitargus® Receives Phase II Thailand Central Research Ethics Committee Approval  FREMONT, CA, June 30, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire –...

ABVC : 0.5488 (-0.20%)

Business Summary

ABCV BIOPHARMA identifies & commercializes drugs & medical devices developed. ABCV BIOPHARMA, formerly known as AMER BRIVISION, is based in FREMONT, CA.

See More

Key Turning Points

3rd Resistance Point 0.6132
2nd Resistance Point 0.5932
1st Resistance Point 0.5710
Last Price 0.5488
1st Support Level 0.5288
2nd Support Level 0.5088
3rd Support Level 0.4866

See More

52-Week High 2.4500
Fibonacci 61.8% 1.6689
Fibonacci 50% 1.4276
Fibonacci 38.2% 1.1864
Last Price 0.5488
52-Week Low 0.4053

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar